Eton Pharmaceuticals (NASDAQ:ETON) Sets New 12-Month High on Earnings Beat

Posted by Francis Steltz on Aug 14th, 2026

Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report) hit a new 52-week high during trading on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $52.85 and last traded at $58.0120, with a volume of 41528 shares changing hands. The stock had previously closed at $40.80.

The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.28. The firm had revenue of $37.59 million during the quarter, compared to analysts’ expectations of $27.11 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%.

Eton Pharmaceuticals News Summary

Here are the key news stories impacting Eton Pharmaceuticals this week:

Positive Sentiment: Q2 earnings and revenue exceeded expectations. Eton reported quarterly EPS of $0.43, compared with the $0.15 consensus estimate, while revenue reached $37.59 million versus expectations of $27.11 million. Zacks cited adjusted EPS of $0.35, up from a loss of $0.10 a year earlier. The results point to improving commercial performance and operating leverage. Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
Positive Sentiment: Analyst remains bullish despite estimate reductions. HC Wainwright maintained a “Buy” rating and a $65 price target, above the stock’s recent opening price of $40.80. That target suggests the firm still sees substantial upside from Eton’s rare-disease portfolio and future product growth. HC Wainwright Issues Negative Outlook for ETON Earnings
Neutral Sentiment: Management discussed the quarterly results and outlook on its earnings call. The call may provide additional detail on product launches, commercial execution and the company’s development pipeline, but the supplied report does not identify a new material announcement or specific guidance change. Eton Pharmaceuticals Q2 2026 Earnings Call Transcript
Negative Sentiment: HC Wainwright reduced its long-term EPS forecasts. Estimates were cut to $1.28 from $1.83 for FY2027, $2.23 from $3.50 for FY2028, $4.25 from $5.85 for FY2029 and $6.53 from $8.65 for FY2030. Although the Buy rating and $65 target were retained, the revisions signal more cautious expectations for Eton’s future earnings growth. HC Wainwright Earnings Estimates

Analyst Ratings Changes

ETON has been the subject of a number of research reports. HC Wainwright lifted their price objective on Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday. Craig Hallum lifted their price target on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Canaccord Genuity Group initiated coverage on shares of Eton Pharmaceuticals in a research note on Thursday, July 16th. They set a “buy” rating and a $60.00 price target for the company. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Eton Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.75.

Read Our Latest Stock Analysis on ETON

Insider Buying and Selling

In related news, Director Jennifer Mckie Adams sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at approximately $1,624,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Krempa sold 19,679 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total transaction of $619,298.13. Following the completion of the sale, the insider directly owned 25,249 shares of the company’s stock, valued at $794,586.03. The trade was a 43.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 150,000 shares of company stock worth $4,853,921 over the last quarter. 16.49% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ETON. BlackRock Inc. bought a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at $68,629,000. Soleus Capital Management L.P. bought a new position in Eton Pharmaceuticals during the second quarter worth about $4,061,000. Millennium Management LLC lifted its holdings in Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after acquiring an additional 217,042 shares in the last quarter. Oberweis Asset Management Inc. acquired a new position in Eton Pharmaceuticals in the third quarter valued at about $4,180,000. Finally, BNP Paribas Financial Markets grew its stake in Eton Pharmaceuticals by 162.0% in the third quarter. BNP Paribas Financial Markets now owns 229,790 shares of the company’s stock valued at $4,993,000 after acquiring an additional 142,094 shares during the period. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Up 42.0%

The firm has a fifty day simple moving average of $38.47 and a 200-day simple moving average of $28.38. The company has a market capitalization of $1.59 billion, a P/E ratio of -815.90 and a beta of 0.86. The company has a quick ratio of 0.88, a current ratio of 1.21 and a debt-to-equity ratio of 0.62.

About Eton Pharmaceuticals

(Get Free Report)

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.